Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
James Udelson MD
James E. Udelson MD Advisory Board
Deepak Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI Advisory Board
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI Advisory Board
See All Experts
featured
Published in Cardiology

Journal Scan / Research · January 23, 2020

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After ACS

Journal of the American College of Cardiology

 

 Save  Recommend
 Share

Additional Info

Journal of the American College of Cardiology
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
J Am Coll Cardiol 2020 Jan 21;75(2)133-144, VA Bittner, M Szarek, PE Aylward, DL Bhatt, R Diaz, JM Edelberg, Z Fras, SG Goodman, S Halvorsen, C Hanotin, RA Harrington, JW Jukema, V Loizeau, PM Moriarty, A Moryusef, R Pordy, MT Roe, P Sinnaeve, S Tsimikas, R Vogel, HD White, D Zahger, AM Zeiher, PG Steg, GG Schwartz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated